ArticleRSC medicinal chemistry2026
Optimizing CRBN-ligands for optical targeted protein degradation.
Article in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PROTACs are heterobifunctional molecules that modulate protein levels through targeted degradation, eliminating both physiological and pathophysiological functionality. Photoswitchable PROTACs (or PHOTACs) expand on this technology by enabling spatial and temporal control through embedded photoswitches. While these elements can be positioned in either the ligand or linker regions, the extent to which new photoswitches can be incorporated directly into CRBN-ligands without compromising degradation efficiency or light responsiveness remains difficult to predict and largely unexplored systematically. Here, we report new synthetic strategies for incorporating heteroarene and functionalized azobenzene photoswitches into lenalidomide ligands to evaluate their compatibility with CRBN-mediated degradation. Arylazopyrazole-based PHOTACs emerged as the most effective, with
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.